Consulting services for clinical operations, development, regulatory, and patient engagement, invoiced to the Company
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Paul J. Hastings
Also a director
Chief Executive Officer
|
66 | Not stated | $2,978,038 | |
|
Nadir Mahmood
President
|
46 |
Since 2024
2 years
|
$1,396,007 | |
|
Shawn Rose
Chief Medical Officer and Head of Research and Development
|
48 |
Since 2025
1 year
|
$1,224,773 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Consulting services for clinical operations, development, regulatory, and patient engagement, invoiced to the Company
Purchased 3,000,000 shares of common stock and 3,000,031 pre-funded warrants in the March 2024 Offering
Purchased 900,000 shares of common stock in the March 2024 Offering
Purchased 2,000,000 shares of common stock in the March 2024 Offering
Loading...